94 search results for: Atopic Dermatitis
Evaluating the cytokine hierarchy in AD and the contributions of IL-4, IL-13, and IL-31 to itch
Join Lisa Swanson, MD, and Gina Mangin, MPAS, PA-C as they discuss the evaluation of the cytokine hierarchy in AD and the contributions of IL-4, IL-13, and IL-31 to itch.
Exploring IL-31–mediated immune modulation and the role of IL-4 signaling in AD-related conjunctivitis
Join Dr. Lisa Swanson and Gina Mangin discussing myths and perceptions on understanding IL-31's role in modulating immune responses and exploring a possible link between IL-4 inhibition and conjunctivitis in AD.
IL-4 Contributes to Systemic Type 2 Inflammation in AD
In this highlight video from the ADVENT AD symposium held at EADV’s 2024 Annual Meeting in Amsterdam, Dr. Stephan Weidinger discusses how IL-4 contributes to systemic type 2 inflammation in AD via several mechanisms, including T cell differentiation, B cell activation and IgE generation, and T regulatory cell inhibition.
Considerations for Disease Modification in AD
In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Eric Simpson explores potential considerations when discussing the concept of disease modification and how early intervention might be disease modifying in AD.
Epidemiology and Pathophysiology of AD in Children
In this expert interview video focusing on topics from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses the epidemiology of AD in children and the role of type 2 cytokines in driving the pathophysiology of the disease
Identification and Management of AD Uncontrolled With Topical Therapies in Children
In this expert interview video focusing on topics from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Perla Lansang discusses how to identify pediatric patients with AD uncontrolled with topical therapies, considerations for the next step in care for these patients, and the potential benefits of early intervention with systemic treatment
Role of Type 2 Inflammation in Skin Barrier Disruption and Itch
In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses how type 2 inflammation contributes to epidermal barrier dysfunction and chronic itch in AD
Persistence of AD From Childhood Into Adulthood
In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert describes how AD can persist into adulthood in many children with moderate-to-severe AD and discusses the risk factors for such persistence.
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?
In this video soundbite from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson explains how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation.
KOL Video Interview – Dr Paula Luna
In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.
KOL Video Interview – Dr Amy Paller
In this exclusive video interview, Dr Amy Paller discusses two topics: 1) The importance of CCL17 (TARC) as a biomarker in pediatric patients with AD, and 2) How IL-4 and IL-13 contribute to skin barrier dysfunction in AD.
Understanding Barriers to Advanced Systemic Therapy in AD
Dr. Jean-David Bouaziz highlights a study describing barriers to initiating advanced systemic therapy for AD at EADV 2025
